Palatin Technologies logo

Palatin TechnologiesNYSE American: PTN

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

15 October 1997

Next earnings report:

14 November 2024

Last dividends:

N/A

Next dividends:

N/A
$24.44 M
-87%vs. 3y high
26%vs. sector
-vs. 3y high
-vs. sector
-219.15
-975%vs. 3y high
1%vs. sector
-99%vs. 3y high
63%vs. sector

Price

pre-market | 50 min ago
$1.25$0.00(0.00%)

Dividend

No data over the past 3 years
$350.00 K-$8.25 M

Analysts recommendations

Institutional Ownership

PTN Latest News

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024
prnewswire.com04 November 2024 Sentiment: -

Oral PL7737 significantly decreased food intake and body weight Oral small molecule melanocortin 4 agonist (MC4R) could address unmet needs and challenges of current obesity treatments Multiple clinical trials targeted in calendar year 2025 for the Company's obesity programs CRANBURY, N.J. , Nov. 4, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system, today announced that preclinical data from the Company's melanocortin 4 receptor (MC4R) selective PL7737 obesity program will be highlighted in a poster presentation at ObesityWeek® 2024, the annual meeting of the Obesity Society held in San Antonio, Texas.

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium
prnewswire.com23 October 2024 Sentiment: POSITIVE

High selectivity for MC4R significantly reduces potential for skin pigmentation MC4R is a well-validated target for treating obesity Clinical studies with highly selective MC4R agonists targeted to commence in calendar year 2025 CRANBURY, N.J. , Oct. 23, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, presented a poster titled "Structural Modification Allows the Removal of Melanocortin Receptor 1 Agonism From Melanocortin Receptor 4 Agonists," at the 19th Annual Peptide Therapeutics Symposium held October 22-23, 2024 in person and virtually in La Jolla, California.

Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
prnewswire.com01 October 2024 Sentiment: POSITIVE

Obesity: Phase 2 Clinical Study with Melanocortin-4 Receptor (MC4R) Agonist plus Glucagon Like Peptide-1 (GLP-1) Patient Dosing Commenced 3Q Calendar Year 2024 Patient Enrollment Expected to be Completed Early 4Q Calendar Year 2024 Topline Results Expected 1Q Calendar Year 2025 Dry Eye Disease (DED): PL9643 MELODY-2 & MELODY-3 Phase 3 Pivotal Clinical Studies FDA Confirms Protocols and Endpoints Patient Enrollment Start Expected 1Q Calendar Year 2025 Topline Results Anticipated 4Q Calendar Year 2025 Potential Partner Collaboration and Funding Discussions Ongoing Male Sexual Dysfunction: Bremelanotide Co-Formulated with a PDE5i for the Treatment of Erectile Dysfunction (ED) in Patients That Do Not Respond to PDE5i Monotherapy Pharmacokinetics Study Expected to Start 1Q Calendar Year 2025 Patient Recruitment in Phase 2/3 Study Anticipated in 2H Calendar Year 2025 Ulcerative Colitis (UC): Oral PL8177 Phase 2 Clinical Study in Active UC Patients Interim Analysis Readout Expected 4Q Calendar Year 2024 Topline Results Anticipated 1Q Calendar Year 2025 Potential Partner Collaboration and Funding Discussions Ongoing Diabetic Nephropathy: Phase 2 BMT 701 Study in Patients with Diabetic Kidney Disease Topline Results Expected 4Q Calendar Year 2024 Teleconference and Webcast to be held on October 1, 2024, at 11:00 AM ET CRANBURY, N.J. , Oct. 1, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal fourth quarter and fiscal year ended June 30, 2024.

Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results
prnewswire.com26 September 2024 Sentiment: POSITIVE

Teleconference and Webcast to be held on October 1, 2024 CRANBURY, N.J. , Sept. 26, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2024 operating results on Tuesday, October 1, 2024, before the open of the U.S. financial markets.

Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
prnewswire.com09 September 2024 Sentiment: POSITIVE

Dry Eye Disease (DED): PL9643 MELODY-2 & MELODY-3 Phase 3 Pivotal Clinical Studies FDA Confirms Protocols and Endpoints Targeting Enrollment Start in 4Q Calendar Year 2024 Topline Results Anticipated 4Q Calendar Year 2025 Potential Collaboration/Funding Discussions Ongoing Obesity: Phase 2 Clinical Study with Melanocortin-4 Receptor (MC4R) Agonist + Glucagon Like Peptide-1 (GLP-1) Patient Dosing Commenced 3Q Calendar Year 2024 Topline Results Expected 1Q Calendar Year 2025 Male Sexual Dysfunction: Development and Clinical Program with Bremelanotide Co-Formulated with a PDE5i for the Treatment of Erectile Dysfunction (ED) in Patients That Do Not Respond to PDE5i Monotherapy Pharmacokinetics Study Expected to Start 1Q Calendar Year 2025 Patient Recruitment in Phase 3 Study Anticipated in 2H Calendar Year 2025 Ulcerative Colitis (UC): Oral PL8177 Phase 2 Clinical Study in Active UC Patients Interim Analysis Readout Expected in 4Q Calendar Year 2024 Topline Results Anticipated 1Q Calendar Year 2025 Potential Collaboration Discussions Ongoing CRANBURY, N.J. , Sept. 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today provided an update on its clinical programs, strategic priorities, and anticipated milestones.

FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)
prnewswire.com28 August 2024 Sentiment: POSITIVE

FDA & Palatin agree on clear regulatory path for PL9643 NDA submission in DED FDA confirms acceptability of protocols and endpoints for remaining MELODY-2 & MELODY-3 Phase 3 Pivotal Clinical Trials in DED Currently anticipate patient enrollment to start in 4Q calendar year 2024 Topline results currently expected in 4Q calendar year 2025 CRANBURY, N.J. , Aug. 28, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced receipt of FDA correspondence confirming the acceptability of the protocols and endpoints for signs and symptoms of PL9643 Phase 3 pivotal clinical trials for dry eye disease (DED).

First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity
prnewswire.com22 August 2024 Sentiment: POSITIVE

Complete enrollment currently expected in 3Q 2024 Topline results expected in 1Q calendar year 2025 Additional studies under assessment for multiple metabolic conditions CRANBURY, N.J. , Aug. 22, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that patient dosing has started for the clinical study entitled: BMT-801: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Study Investigating the Safety, Tolerability, and Effectiveness of the Co-Administration of Bremelanotide with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity (ClinicalTrials.gov Identifier: NCT06565611).

Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds
prnewswire.com21 June 2024 Sentiment: POSITIVE

CRANBURY, N.J. , June 21, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a warrant inducement agreement with an institutional investor to exercise certain outstanding warrants that the Company issued in November 2022 and October 2023 totaling 3,233,277 shares of the Company's common stock for gross proceeds of approximately $6.1 million.

Palatin Technologies (PTN) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com20 May 2024 Sentiment: POSITIVE

Palatin Technologies (PTN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Palatin (PTN) Up 15% on Results From Dry Eye Disease Study
Zacks Investment Research09 April 2024 Sentiment: POSITIVE

Late-stage study results indicate that Palatin's (PTN) experimental drug for dry eye disease demonstrated significant and meaningful improvements in various symptoms.

What type of business is Palatin Technologies?

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.

What sector is Palatin Technologies in?

Palatin Technologies is in the Healthcare sector

What industry is Palatin Technologies in?

Palatin Technologies is in the Biotechnology industry

What country is Palatin Technologies from?

Palatin Technologies is headquartered in United States

When did Palatin Technologies go public?

Palatin Technologies initial public offering (IPO) was on 15 October 1997

What is Palatin Technologies website?

https://palatin.com

Is Palatin Technologies in the S&P 500?

No, Palatin Technologies is not included in the S&P 500 index

Is Palatin Technologies in the NASDAQ 100?

No, Palatin Technologies is not included in the NASDAQ 100 index

Is Palatin Technologies in the Dow Jones?

No, Palatin Technologies is not included in the Dow Jones index

When was Palatin Technologies the previous earnings report?

No data

When does Palatin Technologies earnings report?

The next expected earnings date for Palatin Technologies is 14 November 2024